Morepen Laboratories Limited (NSE:MOREPENLAB)

India flag India · Delayed Price · Currency is INR
64.44
-0.03 (-0.05%)
Jun 6, 2025, 3:30 PM IST
48.65%
Market Cap 35.30B
Revenue (ttm) 18.30B
Net Income (ttm) 1.18B
Shares Out n/a
EPS (ttm) 2.20
PE Ratio 29.91
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,840,731
Average Volume 6,219,523
Open 64.75
Previous Close 64.47
Day's Range 63.50 - 64.89
52-Week Range 42.00 - 100.90
Beta 0.79
RSI 56.97
Earnings Date Aug 7, 2025

About Morepen Laboratories

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermome... [Read more]

Sector Healthcare
Founded 1984
Employees 2,152
Stock Exchange National Stock Exchange of India
Ticker Symbol MOREPENLAB
Full Company Profile

Financial Performance

In 2024, Morepen Laboratories's revenue was 18.30 billion, an increase of 7.52% compared to the previous year's 17.02 billion. Earnings were 1.18 billion, an increase of 22.73%.

Financial Statements

News

Morepen Laboratories secures Rs 50 crore loan facility from Qatar National Bank

Morepen Laboratories Limited has announced that its Board of Directors has approved a financial agreement with Qatar National Bank for a loan facility totalling ₹50 crore. The arrangement, finalized o...

14 days ago - Business Upturn

Morepen Laboratories share price drops 3% as Q4 Ebitda falls 12.6% to Rs 42.3 crore

Shares of Morepen Laboratories fell 3% in early trade on Monday after the company released its consolidated financial results for the fourth quarter of the financial year 2024-25 (Q4 FY25). The market...

24 days ago - Business Upturn

Morepen Laboratories receives SEC clearance for Resmetirom bioequivalence studies

Morepen Laboratories Ltd. has received clearance from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct bioequivalence (BE) studies for Resmetiro...

5 weeks ago - Business Upturn

Morepen Labs shares rally 7% today on this major update – Know More

Shares of Morepen Laboratories Ltd. surged over 7% to ₹58.35 on the NSE in Thursday’s trade following the announcement of four major product launches across critical therapeutic segments. The stock op...

6 weeks ago - Business Upturn

Morepen Labs launches 4 new drugs in April 2025, eyes Rs 1,000 crore formulation business in 5 years

Morepen Laboratories Ltd. on Thursday, April 24, 2025, announced the launch of four new pharmaceutical products—Ticapen, UdoFix, LycoMore, and Acifix—marking a strategic expansion of its branded formu...

6 weeks ago - Business Upturn

Morepen Laboratories to add 1,000 medical representatives in major expansion drive

Morepen Laboratories has announced a bold expansion strategy aimed at significantly increasing its reach within India’s domestic pharmaceutical market. The company plans to hire over 1,000 medical rep...

2 months ago - Business Upturn

Morepen Laboratories shares rise 2% after China approves Loratadine API

Shares of Morepen Laboratories Ltd climbed over 2% to ₹48.81 in Monday’s trade after the company secured a major regulatory milestone. The Center for Drug Evaluation (CDE) under China’s National Medic...

2 months ago - Business Upturn

Morepen Laboratories secures CDE China approval for Loratadine API, expanding global reach

Morepen Laboratories Limited, a global leader in Active Pharmaceutical Ingredient (API) manufacturing, has received approval from the Center for Drug Evaluation (CDE) of China’s National Medical Produ...

2 months ago - Business Upturn

Morepen Laboratories secures Rs 25 crore term loan from Shinhan Bank for business expansion

Morepen Laboratories Limited announced on Saturday, March 29, 2025, that it has entered into a loan agreement with Shinhan Bank for a term loan facility of Rs 25 crore. The company confirmed that the ...

2 months ago - Business Upturn

Morepen Laboratories ventures into online retail pharmacy sector with new step-down subsidiary

Morepen Laboratories Limited has announced its entry into the online retail pharmacy sector with the formation of a step-down subsidiary, Quick Med Private Limited. The company informed the stock exch...

3 months ago - Business Upturn

Morepen Laboratories to establish a new subsidiary for medical devices, acquires 80% stake

Morepen Laboratories Limited has announced the incorporation of a new subsidiary to enhance its capabilities and expand its business operations. The company will hold an 80% equity stake in the new en...

5 months ago - Business Upturn

Morepen Laboratories Ltd (BOM:500288) Q2 2025 Earnings Call Highlights: Strong Profit Growth ...

Morepen Laboratories Ltd (BOM:500288) Q2 2025 Earnings Call Highlights: Strong Profit Growth and Strategic Expansion

7 months ago - GuruFocus

Morepen Labs shares surge 21% in last one week

Morepen Laboratories Ltd., a pharmaceutical company, has seen its share price increase by 21% over the last week. As of 12:08 PM on August 26, 2024, the stock is trading at ₹84.14 on the NSE, up 5.03%...

10 months ago - Business Upturn